14/11/2016 11:19:07

NeuroSearch found guilty of market manipulation in Supreme Court case

Related content
20 Jun - 
Publication of offer document by Nordic Transport Group..
31 May - 
Decision on launch of voluntary offer
25 May - 
NeuroSearch A/S: Publication of offer document
Related debate
06 Jun - 
Netop , jeg mener ikke det er lovligt at købe højere en..
06 Jun - 
Nej, det er måske ikke lovligt at købe højere end man b..
06 Jun - 
Nej, det kan forhåbentlig ikke tænkes! Det giver vel he..

Announcement

14 November 2016

The Danish Supreme Court today upheld the Eastern High Court’s decision in a case in which the State Prosecutor for Serious Economic and International Crime had charged NeuroSearch with market manipulation contrary to the Danish Securities Trading Act and the Market Abuse Regulation. The company was further ordered to pay a fine of DKK 5 million.

The charge was brought following NeuroSearch’s announcement in February 2010 in which the company reported top-line results from a clinical phase III study on its drug candidate Huntexil®.

Chairman of the board of directors, Karin Garre, says in a comment:

"It is very regrettable that the Supreme Court has decided to uphold the High Court’s judgment considering that the High Court acquitted the company’s former CEO on the same count. NeuroSearch of course will respect the Supreme Court's ruling that the company is responsible for the announcement concerning the outcome of a clinical study in 2010 contained misleading signals about the market price so that it amounted to market manipulation. This does not reflect NeuroSearch’s view of the situation and that is why we decided to refer the matter to the Supreme Court. With this ruling, the company will work with a view to rapidly decide the future of the company.”

Following the Supreme Court judgment, the board of directors will now assess NeuroSearch’s future and provide the shareholders with the board’s recommendations on the steps to be taken.

The judgment does not affect the company’s expectations for the annual results in 2016.

Karin Garre                                                 Allan Andersen

Chairman of the Board                                CEO

Contact

Allan Andersen, CEO, telephone: +454016 3864.

About NeuroSearch

NeuroSearch A/S (NEUR) is listed on NASDAQ Copenhagen A/S.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care
2
BIOLIFE4D Modifies its Regulation A+ (Mini-IPO) Offering Due to Popular Demand
3
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)
4
Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
5
Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

Related stock quotes

NeuroSearch A/S 4.610 0.4% Stock price increasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
24 June 2018 06:02:20
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-24 07:02:20 - 2018-06-24 06:02:20 - 1000 - Website: OKAY